Innovative buyout structured around success of Actimis’ leading asthma compound.

Boehringer Ingelheim will acquire Actimis Pharmaceuticals through a structured buyout in which Boehringer Ingelheim will acquire shares of Actimis depending on the achievement of several successive milestones with Actimis’ leading asthma compound AP768.

If AP768, currently in Phase I development, is successfully advanced into a Phase III, Boehringer Ingelheim will own 100% of Actimis’ shares. Upon successful completion of the entire development program, the total deal will be worth $515 million. 

AP768 interacts with CRTH21, a target for asthma and allergic rhinitis. Previous to the currently ongoing Phase I trial, the compound was shown to have a more effective mechanism of action across multiple available animal models compared to currently marketed leukotriene receptor antagonists, according to the companies.

Related Links:

Researchers Discover SNP Linked to Asthma

Using Multi-Pathway Target Knockdown

Managing Asthma and COPD Treatments

Previous articleTaconic and PhenoPro Ally to Offer Characterized Mouse Models
Next articleGene Variants Linked to Metabolic Syndrome and HDL Cholesterol Levels Identified